|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
2
|
Rustgi AK and El-Serag HB: Esophageal
carcinoma. N Engl J Med. 371:2499–2509. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siewert JR and Ott K: Are squamous and
adenocarcinomas of the esophagus the same disease? Semin Radiat
Oncol. 17:38–44. 2007. View Article : Google Scholar
|
|
4
|
Ou Y, Ma L, Ma L, Huang Z, Zhou W, Zhao C,
Zhang B, Song Y, Yu C and Zhan Q: Overexpression of cyclin B1
antagonizes chemotherapeutic-induced apoptosis through PTEN/Akt
pathway in human esophageal squamous cell carcinoma cells. Cancer
Biol Ther. 14:45–55. 2013. View Article : Google Scholar :
|
|
5
|
Tong Q, Zhang W, Jin S, Li S and Chen Z:
The relationship between p27(kip1) expression and the change of
radiosensitivity of esophageal carcinoma cells. Scand J
Gastroenterol. 46:173–176. 2011. View Article : Google Scholar
|
|
6
|
Imoto I, Yang ZQ, Pimkhaokham A, Tsuda H,
Shimada Y, Imamura M, Ohki M and Inazawa J: Identification of cIAP1
as a candidate target gene within an amplicon at 11q22 in
esophageal squamous cell carcinomas. Cancer Res. 61:6629–6634.
2001.PubMed/NCBI
|
|
7
|
Dhar R, Persaud SD, Mireles JR and Basu A:
Proteolytic cleavage of p70 ribosomal S6 kinase by caspase-3 during
DNA damage-induced apoptosis. Biochemistry. 48:1474–1480. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fingar DC, Richardson CJ, Tee AR, Cheatham
L, Tsou C and Blenis J: mTOR controls cell cycle progression
through its cell growth effectors S6K1 and 4E-BP1/eukaryotic
translation initiation factor 4E. Mol Cell Biol. 24:200–216. 2004.
View Article : Google Scholar :
|
|
9
|
Neufeld TP: TOR-dependent control of
autophagy: biting the hand that feeds. Curr Opin Cell Biol.
22:157–168. 2010. View Article : Google Scholar :
|
|
10
|
Ganley IG, Lam du H, Wang J, Ding X, Chen
S and Jiang X: ULK1.ATG13.FIP200 complex mediates mTOR signaling
and is essential for autophagy. J Biol Chem. 284:12297–1305. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zinzalla V, Stracka D, Oppliger W and Hall
MN: Activation of mTORC2 by association with the ribosome. Cell.
144:757–768. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oh WJ, Wu CC, Kim SJ, Facchinetti V,
Julien LA, Finlan M, Roux PP, Su B and Jacinto E: mTORC2 can
associate with ribosomes to promote cotranslational phosphorylation
and stability of nascent Akt polypeptide. EMBO J. 29:3939–3951.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cornu M and Hall MN: mTORC1 and mTORC2 in
energy homeostasis. The Enzymes: Structure, Function and Regulation
of TOR Complexes from Yeasts to Mammals. Tamanoi F and Hall MN:
Academic Press; Amsterdam: pp. 263–278. 2010, View Article : Google Scholar
|
|
14
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Um SH, Frigerio F, Watanabe M, Picard F,
Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J
and Thomas G: Absence of S6K1 protects against age- and
diet-induced obesity while enhancing insulin sensitivity. Nature.
431:200–205. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ly C, Arechiga AF, Melo JV, Walsh CM and
Ong ST: Bcr-Abl kinase modulates the translation regulators
ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia
cells via the mammalian target of rapamycin. Cancer Res.
63:5716–5722. 2003.PubMed/NCBI
|
|
18
|
Kharas MG, Deane JA, Wong S, O'Bosky KR,
Rosenberg N, Witte ON and Fruman DA: Phosphoinositide 3-kinase
signaling is essential for ABL oncogene-mediated transformation of
B-lineage cells. Blood. 103:4268–4275. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu Y and Li X: The research progress of
p70S6K1 and 4E-BPs of the AKt/mTOR signal pathway in promoting the
occurrence of tumor. J Modern Oncol. 24:847–850. 2016.
|
|
20
|
Xu Y, Liu F, Zhou LP and Zhao XH: c-IAP1
expression and tumor chemosensitivity in esophageal squamous cell
carcinoma. World Chin J Digestol. 19:1138–1144. 2011.In
Chinese.
|
|
21
|
Wang Q, Huang Y, Ni Y, Wang H and Hou Y:
siRNA targeting midkine inhibits gastric cancer cells growth and
induces apoptosis involved caspase-3,8,9 activation and
mitochondrial depolarization. J Biomed Sci. 14:783–795. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu MY, Hou GQ, Zhang Y, Bei WJ and Yan
AH: Effects of mTOR siRNA on mTOR/p70S6K signaling pathway in
esophageal squamous cell carcinoma cells and the growth of
transplanted tumor in nude mice. Zhonghua Zhong Liu Za Zhi.
33:334–339. 2011.In Chinese. PubMed/NCBI
|
|
23
|
Krenn L and Kopp B: Bufadienolides from
animal and plant sources. Phytochemistry. 48:1–29. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yin PH, Liu X, Qiu YY, Cai JF, Qin JM, Zhu
HR and Li Q: Anti-tumor activity and apoptosis-regulation
mechanisms of bufalin in various cancers: new hope for cancer
patients. Asian Pac J Cancer Prev. 13:5339–5343. 2012. View Article : Google Scholar
|
|
25
|
Li D, Qu X, Hou K, Zhang Y, Dong Q, Teng
Y, Zhang J and Liu Y: PI3K/Akt is involved in bufalin-induced
apoptosis in gastric cancer cells. Anticancer Drugs. 20:59–64.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhai XF, Fang FF, Liu Q, Meng YB, Guo YY
and Chen Z: miR-181a contributes to bufalin-induced apoptosis in
PC-3 prostate cancer cells. BMC Complement Altern Med. 13:3252013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qi F, Inagaki Y, Gao B, Cui X, Xu H,
Kokudo N, Li A and Tang W: Bufalin and cinobufagin induce apoptosis
of human hepato-cellular carcinoma cells via Fas- and
mitochondria-mediated pathways. Cancer Sci. 102:951–958. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takai N, Ueda T, Nishida M, Nasu K and
Narahara H: Bufalin induces growth inhibition, cell cycle arrest
and apoptosis in human endometrial and ovarian cancer cells. Int J
Mol Med. 21:637–643. 2008.PubMed/NCBI
|
|
29
|
Xie CM, Chan WY, Yu S, Zhao J and Cheng
CH: Bufalin induces autophagy-mediated cell death in human colon
cancer cells through reactive oxygen species generation and JNK
activation. Free Radic Biol Med. 51:1365–1375. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee DY, Yasuda M, Yamamoto T, Yoshida T
and Kuroiwa Y: Bufalin inhibits endothelial cell proliferation and
angiogenesis in vitro. Life Sci. 60:127–134. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xia J, Jiang M and Jiang Y: The research
progress of the anti-tumor effect of toad venom and its effective
components in vitro. Modern Oncol. 16:1441–1444. 2008.In
Chinese.
|
|
32
|
Yamada K, Hino K, Tomoyasu S, Honma Y and
Tsuruoka N: Enhancement by bufalin of retinoic acid-induced
differentiation of acute promyelocytic leukemia cells in primary
culture. Leuk Res. 22:589–595. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu Y, Chen M, Jin XF, Qian C, Xu XM and
Zhang X: Research progress of in vitro and in vivo anti-tumor
effects and formulation of bufalin. Zhongguo Zhong Yao Za Zhi.
39:2829–2833. 2014.In Chinese. PubMed/NCBI
|
|
34
|
Qiu DZ, Zhang ZJ, Wu WZ and Yang YK:
Bufalin, a component in Chansu, inhibits proliferation and invasion
of hepatocellular carcinoma cells. BMC Complement Altern Med.
13:1852013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ding Y, Wang XL and Deng HY: Mechanism of
bufalin affecting the proliferation and migration of human
esophageal carcinoma cells through inhibiting the activity of
Raf/MEK/ERK pathway. Chinese General Practice. 212015.In
Chinese.
|
|
36
|
Easley CA IV, Ben-Yehudah A, Redinger CJ,
Oliver SL, Varum ST, Eisinger VM, Carlisle DL, Donovan PJ and
Schatten GP: mTOR-mediated activation of p70S6K induces
differentiation of pluripotent human embryonic stem cells. Cell
Reprogram. 12:263–273. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Smolewski P: Recent developments in
targeting the mammalian target of rapamycin (mTOR) kinase pathway.
Anticancer Drugs. 17:487–494. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang YJ, Dai Q, Sun DF, Xiong H, Tian XQ,
Gao FH, Xu MH, Chen GQ, Han ZG and Fang JY: mTOR signaling pathway
is a target for the treatment of colorectal cancer. Ann Surg Oncol.
16:2617–2628. 2009.In Chinese. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li G, Shan C, Liu L, Zhou T, Zhou J, Hu X,
Chen Y, Cui H and Gao N: Tanshinone IIA inhibits HIF-1α and VEGF
expression in breast cancer cells via
mTOR/p70S6K/RPS6/4EBP1signaling pathway. PLoS One.
10:e01174402015.In Chinese. View Article : Google Scholar
|
|
40
|
Saraswati S, Kumar S and Alhaider AA:
α-santalol inhibits the angiogenesis and growth of human prostate
tumor growth by targeting vascular endothelial growth factor
receptor 2-mediated AKT/mTOR/P70S6K signaling pathway. Mol Cancer.
12:1472013. View Article : Google Scholar
|
|
41
|
Shin JM, Jeong YJ, Cho HJ, Park KK, Chung
IK, Lee IK, Kwak JY, Chang HW, Kim CH, Moon SK, et al: Melittin
suppresses HIF-1α/VEGF expression through inhibition of ERK and
mTOR/p70S6K pathway in human cervical carcinoma cells. PLoS One.
8:e693802013.In Chinese. View Article : Google Scholar
|
|
42
|
Zheng J: mTOR signal pathway and tumor.
Life Sciences. 18:261–265. 2006.
|
|
43
|
Pan Z, Zhang L and Jiang J: The research
progress of mTOR. Chin J Cell Biol. 28:395–398. 2006.
|
|
44
|
Jefferies HB, Fumagalli S, Dennis PB,
Reinhard C, Pearson RB and Thomas G: Rapamycin suppresses 5′TOP
mRNA translation through inhibition of p70s6k. EMBO J.
16:3693–3704. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cheng HD, Zhao QN, Song WD, Sarengaowa and
Liu F: The current research of the component p-P70S6K of mTOR
signal pathway and colon cancer. Journal of Disease Monitor and
Control. 6:78–79. 2012.
|
|
46
|
Asimomytis A, Karanikou M, Rodolakis A,
Vaiopoulou A, Tsetsa P, Creatsas G, Stefos T, Antsaklis A,
Patsouris E and Rassidakis GZ: mTOR downstream effectors, 4EBP1 and
eIF4E, are overexpressed and associated with HPV status in
precancerous lesions and carcinomas of the uterine cervix. Oncol
Lett. 12:3234–3240. 2016.PubMed/NCBI
|
|
47
|
Xu Y and Zhao XH: IAP family and
IAP-targeted therapy. Life Sciences. 22:161–168. 2010.
|
|
48
|
Zhang S, Ding F, Luo A, Chen A, Yu Z, Ren
S, Liu Z and Zhang L: XIAP is highly expressed in esophageal cancer
and its downregulation by RNAi sensitizes esophageal carcinoma cell
lines to chemotherapeutics. Cancer Biol Ther. 6:973–980. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cong YM, Liu P, Jin DP, et al: The
relationship of Bcl-2 family with cell apoptosis. J Chin Med Res.
8:125–127. 2008.In Chinese.
|
